Short Interest in Invivyd, Inc. (NASDAQ:IVVD) Expands By 8.4%

Invivyd, Inc. (NASDAQ:IVVD) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,980,000 shares, an increase of 8.4% from the December 15th total of 3,670,000 shares. Approximately 5.3% of the company’s stock are sold short. Based on an average daily volume of 958,500 shares, the short-interest ratio is currently 4.2 days.

Invivyd Price Performance

NASDAQ IVVD opened at $0.41 on Monday. The stock has a market capitalization of $48.61 million, a price-to-earnings ratio of -0.21 and a beta of 0.64. Invivyd has a 1-year low of $0.38 and a 1-year high of $5.20. The business’s fifty day moving average price is $0.58 and its 200-day moving average price is $0.88.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. HC Wainwright decreased their target price on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Morgan Stanley cut their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Invivyd in a research note on Friday, January 10th. Finally, EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $7.89.

Insider Buying and Selling

In other news, Director Terrance Mcguire sold 160,400 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total value of $94,636.00. Following the sale, the director now directly owns 4,202,679 shares of the company’s stock, valued at $2,479,580.61. The trade was a 3.68 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold a total of 816,466 shares of company stock valued at $423,214 over the last ninety days. Company insiders own 17.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Proficio Capital Partners LLC bought a new position in shares of Invivyd in the 3rd quarter worth approximately $27,000. XTX Topco Ltd raised its holdings in Invivyd by 68.1% in the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after purchasing an additional 15,376 shares during the period. Rhumbline Advisers lifted its position in Invivyd by 4,434.1% during the second quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock valued at $92,000 after purchasing an additional 82,164 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in Invivyd during the second quarter valued at about $115,000. Finally, Barclays PLC increased its position in Invivyd by 179.6% in the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after buying an additional 75,780 shares in the last quarter. Institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.